# MAV/06

Type: Product

Source: Biotech Intelligence Brief — https://getbiobrief.com/entity/mav06
Canonical HTML page: https://getbiobrief.com/entity/mav06

## Timeline

- **2026-03-11**: 30-Year Review Publication — Comprehensive review paper summarizing three decades of data is published in a peer-reviewed journal.
- **2020**: Barycel Launch — GC Biopharma launches an improved version of its varicella vaccine based on the MAV/06 strain.
- **2000**: Global Expansion — The MAV/06-based vaccine is exported to over 30 countries and integrated into national immunization programs.
- **1993**: Initial Development — GC Biopharma begins the clinical application of the MAV/06 varicella strain.

## Recent coverage (1 stories)

### GC Biopharma Validates Proprietary MAV/06 Varicella Strain with 30-Year Data Review
2026-03-11 08:36:44 · Sentiment: Neutral · Impact: 5/10 · Sources: 2

GC Biopharma has published a comprehensive review paper detailing three decades of clinical and real-world data for its proprietary MAV/06 varicella vaccine strain. This publication underscores the long-term safety and efficacy of the strain, which has been a cornerstone of the company's global vaccine portfolio and international procurement strategy.
Full story: https://getbiobrief.com/story/gc-biopharma-mav06-varicella-vaccine-review

---
This page is a machine-readable summary. Sentiment measures the directional read of each development for this entity, not the tone of the reporting; impact weights consequence, not syndication reach. See https://getbiobrief.com/guides/methodology for the full editorial methodology.